Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ciclo 21 is a combined oral contraceptive (COC) containing a fixed-dose combination of 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol. Manufactured by the Brazilian pharmaceutical company União Química, it is used for the prevention of pregnancy and acts as a generic equivalent to the reference drug Nordette. The medication functions by suppressing the release of pituitary gonadotropins, specifically luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which inhibits follicular maturation and prevents ovulation. Furthermore, it increases the viscosity of cervical mucus to hinder sperm penetration and alters the endometrial lining to decrease the probability of implantation. It is typically administered as a once-daily pill for 21 consecutive days followed by a 7-day hormone-free interval.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ciclo 21.